Redefining Metabolic Dysfunction-Associated Steatohepatitis Treatment: Managed Care Insights on New Therapies Targeting Metabolic Dysfunction

Program Description

Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive, inflammatory liver disease that represents the most severe form of metabolic dysfunction–associated steatotic liver disease (MASLD). Driven by the accumulation of fat in the liver and other metabolic disturbances, MASH can advance to fibrosis, cirrhosis, hepatocellular carcinoma, and end-stage liver failure. Because MASH is often asymptomatic until advanced stages, early testing and accurate identification of at-risk individuals are crucial to prevent progression and improve long-term outcomes. This program will equip pharmacists and managed care professionals with up-to-date knowledge on MASH pathophysiology, clinical presentation, and disease burden, alongside emerging data from pivotal clinical trials of approved and investigational therapies. Participants will explore recent guideline updates and evidence-based, personalized treatment approaches tailored to disease severity, comorbidities, and patient-specific factors. The program will also address the rapidly evolving therapeutic landscape, the importance of early identification and intervention, and managed care strategies to optimize access, outcomes, and health care resource utilization.

Target audience: Specialty Pharmacists, Managed Care Pharmacists

Type of activity: Application

Release date: June 16, 2026

Expiration date: August 16, 2026

Time to complete activity: 1.0 hour

Learner level: Foundational, Intermediate 

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the metabolic drivers of metabolic dysfunction-associated steatohepatitis (MASH), along with its key clinical manifestations, common comorbid conditions, diagnostic evaluation, and overall impact on disease burden.
• Interpret current data and guideline recommendations underpinning FDA-approved therapies for MASH as well as the mechanisms of action of late-stage investigational agents.
• Apply managed care strategies that facilitate timely diagnosis and equitable access to evidence-based MASH treatments, with the goal of improving clinical outcomes and mitigating downstream health care costs.

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-23-187-L01-P. The activity is available for CE credit through June 16, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Drake Reiter, Pharm D has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Comprehensive Care Sustainability Collaborative, Impact Education, National Bleeding Disorders Foundation, Health Institutes Research Center, Eversana, COEUS, Havas, BioMedical Insights, Capvision, GLG, Avalon Healthcare Solutions, MMIT, SUN Pharma (via COEUS)

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Katie Naspo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms